基蛋生物收盘上涨1.70%，滚动市盈率21.05倍，总市值42.50亿元

Group 1 - The core viewpoint of the news highlights the current performance and market position of the company, Jidan Biotechnology, in the medical device industry, noting its low PE ratio compared to industry averages [1] - As of July 16, Jidan Biotechnology's closing price was 8.38 yuan, with a PE ratio of 21.05, marking a new low in 70 days, and a total market capitalization of 4.25 billion yuan [1] - The company ranks 48th in the medical device industry, which has an average PE ratio of 51.87 and a median of 37.48 [1] Group 2 - Jidan Biotechnology primarily engages in the research, production, sales, and service of in vitro diagnostic reagents and instruments, being a key supplier in the POCT field [1] - The latest quarterly report for Q1 2025 shows the company achieved revenue of 244 million yuan, a year-on-year decrease of 24.08%, and a net profit of 64.31 million yuan, down 25.24%, with a gross margin of 77.15% [1] - As of the Q1 2025 report, four institutions held shares in Jidan Biotechnology, totaling 28.14 million shares with a market value of 236 million yuan [1]